Proteogenomic characterization of pediatric hematopoietic malignancies

Acute myeloid leukemia (AML) is the second most common pediatric hematologic malignancy with approximately 600 new cases per year among patients under 20 years of age. Although AML accounts for only about 20% of leukemias in children, it is responsible for more than half of pediatric leukemia deaths. The prognosis of children with AML has improved greatly over the past 30 years, attributable largely to the intensification and standardization of chemotherapy regimens. Still, only 60% of pediatric patients with AML will be cured with standard therapy. By undertaking an integrated genomic, transcriptomic and proteomic approach we aim to define the AML proteogenomic landscape, which will facilitate novel target discovery. A proteogenomic characterization of AML sarcoma organoids generated by the CBTN will allow us to study the molecular and cellular changes that underpin myeloid sarcomas.